Discuss This Drug

enasidenib

CHEBI:CHEBI_145374

Definition

A 1,3,5-triazine which is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has been approved for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML).

Chemical Information

Molecular Formula
C19H17F6N7O
Molecular Mass
473.383
Charge
0
SMILES
C1(=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NCC(O)(C)C)NC=3C=CN=C(C3)C(F)(F)F
InChI
InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
InChIKey
DYLUUSLLRIQKOE-UHFFFAOYSA-N

Alternative Names

  • 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol
  • AG 221
  • AG-221
  • CC-90007
  • enasidenib
  • enasidenibum
  • Idhifa

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

DRON_00010000
1940332
oboInOwl#hasDbXref
Wikipedia:Enasidenib
core#notation
CHEBI:145374

Additional References

Wikipedia:Enasidenib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1940332
oboInOwl#hasDbXref
Wikipedia:Enasidenib
oboInOwl#id
CHEBI:145374
core#notation
CHEBI:145374
brand_name
Idhifa
brand_name_base
Idhifa
rxcui
1940376
product_type
HUMAN PRESCRIPTION DRUG
marketing_category
NDA
listing_expiration_date
20251231
route
ORAL
active_ingredient_strength
50 mg/1
dosage_form
TABLET, FILM COATED
marketing_start_date
20170801
package_marketing_start_date
20170801
labeler_name
Celgene Corporation
manufacturer_name
Celgene Corporation
pharm_class
Isocitrate Dehydrogenase 2 Inhibitors [MoA]
generic_name
enasidenib mesylate
product_ndc
59572-705
application_number
NDA209606
spl_id
01043cba-240a-4cbc-9466-fded4c738efb
active_ingredient_name
ENASIDENIB MESYLATE
package_ndc
59572-705-30
package_description
30 TABLET, FILM COATED in 1 BOTTLE (59572-705-30)
unii
UF6PC17XAV
spl_set_id
a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_145410
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
has_treatment
http://purl.obolibrary.org/obo/DOID_0111352
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect5362
owl#annotatedSource
t112508
owl#someValuesFrom
t3174714